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ABSTRACT
A considerable number of patients arriving in dental offices are being treated with ongoing medication for a
variety of chronic diseases. As a result, dentists must be familiar with the potential side effects these
therapeutic agents may have on the tissues of the oral cavity, and in particular on the salivary gland.
Salivary gland function may be altered by a wide range of medications, leading to effects such as xero-
stomia, hyposalivation, hypersalivation or even swelling of the glands. These disorders can cause a variety
of other health complications. This review will focus on the most common groups of drugs responsible for
salivary gland dysfunction, including psychoactive drugs, antidepressants, antipsychotics, antihypertensives,
and antihistamines.
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INTRODUCTION
Patients under chronic medication therapy are common, and dentists must be aware of the
possible side effects caused by different drugs, as well as the mechanisms by which these
medications act. A large number of both prescribed and non-prescribed drugs taken for the
treatment of chronic diseases of the cardiovascular, urogenital, respiratory, neurologic, gastro-
intestinal systems (among others) may affect oral health. For example, many of the medications
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can cause xerostomia, caries and other lesions to the oral mucosa [1]. The most frequently
reported complaint related to medication usage is salivation dysfunction, and specifically dry
mouth sensation.
Salivation is defined as the secretion of fluids by the salivary glands, and is essential in several
physiological processes, including digestion, food lubrication, buffering capacity, wound healing,
defense against chemical and mechanical injuries, and the maintenance of the oral cavity [1].
The major salivary glands in the human body are the parotid glands, the submandibular glands
and the sublingual glands. Saliva is an exocrine secretion, consisting of electrolytes and proteins
including enzymes, antimicrobial proteins, glycoproteins, immunoglobulins, growth factors, and
mucins, however the precise composition of saliva varies based on which gland it originates
from. The salivary glands are largely regulated by the autonomic nervous system (ANS);
parasympathetic and sympathetic nerves control the secretion of saliva by acting through re-
ceptors found on salivary acinar cells (Fig. 1) [2]. In addition to the control of the glands by the
ANS, some gastrointestinal hormones can also affect the composition and flow rate of saliva [3].
Secretion of the two major components of saliva is a result of distinct stimulation by the
ANS. Parasympathetic stimulation of the acinar cells results in secretion of the fluid component,
including ions, while sympathetic stimulation of the glands leads to secretion of the protein
component [1]. Secretion of chloride and sodium contributes to the production of an isotonic
fluid by the acinar cells. There are five subtypes of muscarinic acetylcholine receptors, and the
one that is responsible for the parasympathetic neurotransmission of the salivary glands is the
M3 muscarinic receptor. Acetylcholine binds the M3 receptor located on the acinar cells,
stimulating secretion of water and sodium chloride forming an isotonic saliva. However, as
saliva travels through the salivary ducts, sodium and chloride ions are reabsorbed and
Fig. 1. Innervation of salivary glands. Shown are the sympathetic and parasympathetic pathways inner-
vating the different salivary glands. Sympathetic innervation of all salivary glands arises from the superior
cervical ganglion after which fibers pass through the carotid plexus to their target organs. Parasympathetic
innervation is more complex. Nerve fibers in the parotid gland originate from the inferior salivary nucleus,
and are carried by the glossopharyngeal nerve (CN IX). These fibers pass through the otic ganglion, and are
then carried by auriculotemporal nerve of the mandibular division of the trigeminal nerve (CN V3).
Parasympathetic nerve fibers in the submandibular and sublingual glands originate in the superior salivary
nucleus and are carried by the chorda tympani nerve of Facial nerve (CN VII)
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bicarbonate and potassium ions are secreted into the saliva from the ductal cells. These two
processes turn the saliva into a hypotonic fluid as it enters the oral cavity [2].
The process of secretion is thought to be dependent on two mechanisms which act through
either a calcium mediated pathway or a cyclic adenosine monophosphate (cAMP) mediated
pathway [4]. The M3 receptor is a G-protein coupled receptor. After acetylcholine binds the
receptor, the associated G-protein activates phospholipase C (PLC). PLC then hydrolyzes
phosphatidylinositol 4,5-bisphosphonate (PIP2) into inositol 1,4,5-triphosphate (IP3) and
diacylglycerol (DAG). As IP3 binds its receptor (IP3R), located on the endoplasmic reticulum
(ER), calcium ions are released from the ER into the cytosol leading to the secretion of enzymes,
fluid and ions.
In contrast, sympathetic stimulation of the acinar cells involves the adrenergic receptors.
Receptors such as a1 and b1 adrenergic receptors, H2 histamine receptors, etc. mediate their
function via the cAMP-protein kinase A (PKA) pathway. Sympathetic stimulation of the acinar
cells involves binding of either epinephrine or norepinephrine to an adrenergic receptor on the
cell membrane. Subsequent activation of the G-protein leads to activation of adenylate cyclase
and conversion of ATP to cAMP. The resulting increased intracellular concentration of cAMP
leads to activation of PKA. PKA plays a major role in several cellular functions, including
secretion of the protein component of saliva.
Other receptors in addition to the M3 receptor, such as the NK1 receptor also regulate
salivation via the IP3/DAG pathway. In addition, the main inhibitory neurotransmitter in the
central nervous system (CNS), GABA, is involved in decreasing fluid and amylase secretion by
acting on the GABA-A receptor located on the salivary gland [4, 5].
The function and product of the salivary gland may be altered by a wide range of medi-
cations, leading to effects such as xerostomia, hyposalivation, hypersalivation or swelling of the
glands. These undesirable effects can be related to lower concentrations of calcium and phos-
phate in the saliva as well as its decreased flow rate. Another contributing factor is decreased
secretion of growth factors into saliva. Growth factors and salivary mucins secreted by the
salivary glands play a major role in the preservation of the oral mucosa integrity and wound
healing. One important characteristic of these growth factors is to trap water, which aids in
preventing tissue dehydration and assisting regeneration. For example, epidermal growth factor
is found in a variety of tissues throughout the human body, but is also essential in the salivary
glands, where it has an important role in oral wound healing [6].
HYPERSALIVATION
Hypersalivation is a state of over-secretion of saliva by the salivary glands. It can eventually lead
to sialorrhea which can cause social embarrassment and may also lead to other consequences,
including choking and aspiration pneumonia. The main medications which have hypersaliva-
tion as a common side-effect are a subset of psychoactive drugs which are used both by pre-
scription and illegally (Table 1). In addition to their effects on salivary flow rates, these drugs
may also change the composition of the saliva. Hypersalivation is an end-result of several
different effects of these drugs: depletion of noradrenaline from central stores, excessive stim-
ulation of M3 and dopamine D2 receptors, as well as inhibition of a2 adrenergic receptors [7].
For example, clozapine is an atypical antipsychotic drug, prescribed for patients with treatment-
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resistant schizophrenia and associated with an elevated risk of blood disorders and
hypersalivation.
HYPOSALIVATION AND XEROSTOMIA
Xerostomia is defined as a subjective complaint of dry mouth. Xerostomia affects over 30% of
patients older than 65 [8]. Logic might suggest that patients reporting xerostomia would show
decreased salivary flow, but in many cases, patients do not have objective signs of hypo-
salivation. Xerostomia is an end-result of various causes and can harm the oral cavity. Hypo-
salivation is a non-subjective state and in most cases, it is accompanied by xerostomia. The
average salivary flow rate under stimulated conditions is 1.5–2.0 mL/min and is 0.3–0.4 mL/min
under unstimulated conditions. Hyposalivation is defined as stimulated and unstimulated
salivary flow rates below 0.5 and 0.1 mL/min, respectively [9]. In addition to causing discomfort
to the patient, hyposalivation likely affects the oral microbiome [10] and increases the proba-
bility of dental caries, fungal and bacterial infections, and oral lesions [6, 7]. Patients with
hyposalivation experience taste disturbance and exhibit difficulty masticating and swallowing.
Hundreds, if not thousands of drugs, can induce xerostomia as a side-effect. Some of these
agents cause a subjective complaint of dry mouth, while others actually induce hyposalivation by
multiple mechanisms, such as inhibition of M3 muscarinic receptors and a1 adrenergic re-
ceptors, inhibition of noradrenaline uptake, or stimulation of a2 adrenergic receptors [4, 7].
Many mechanisms of action have been suggested to contribute to xerostomia. Some drugs
compete with acetylcholine in both sympathetic and parasympathetic ganglia while other drugs
compete with the release of acetylcholine at the parasympathetic effector junction. Another
mechanism occurs at the higher centers of the brain, where stimulation of a subset of adre-
noreceptors in the frontal cortex can result in inhibitory effects on salivary nuclei. Certain
medications can also produce xerostomia without having an effect on neural pathways (Table 2).
For example, these medications are mostly inhaled and can produce sensation of mouth dryness
without altering the salivary flow. Another hypothesis suggests that dry mouth sensation may
result from decreased fluid volume and loss of electrolytes secondary to increased urination and
dehydration caused by medication usage [9].
Among all the mechanisms described above, the anticholinergic mechanism is a primary
contributor in many cases of hyposalivation. Among the most common drugs that can cause dry
mouth by interfering with the ANS signaling involved in regulation of saliva production are
several groups of antidepressants, antipsychotics, b blockers and antihistamines. These drugs are
widely used, and dry mouth is a real and common occurrence in patients treated for psychiatric,
hypertensive and urinary problems [4, 7]. Further exploration of these drug groups is considered
below.
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Antidepressants
Antidepressants such as monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants
(TCAs) can lead to increased serotonergic or noradrenergic effects. TCAs can also cause the
inhibition of cholinergic, histaminic and a1 adrenergic receptors, resulting in xerostomia. A
study investigating the effects of several antidepressants has found that TCAs can lead to a
significant decrease in salivary flow rate. Additionally, these drugs can cause a decrease in the
salivary concentration of sodium, and an increase in the concentration of potassium. These
effects are a direct consequence of muscarinic receptor inhibition. In contrast, drugs in the SSRI
(selective serotonin reuptake inhibitors) class had no effect on these parameters. Another study
reviewing the effects of the TCA dothiepin in non-depressed patients confirmed that this drug
can decrease the stimulated salivary flow rate of the parotid gland [11]. An additional consid-
eration with TCAs is sex-related differences in responses. It has been suggested that women
might have a lower rate of serotonin synthesis in the brain, and as a result, they could be more
sensitive than men to the depressant effects of tryptophan depletion [12].
Antihypertensives
Clonidine, guanfacine, reserpine and methyldopa are examples of classic, centrally acting an-
tihypertensives. These agents stimulate a2 adrenergic receptors in the brain stem, leading to
peripheral sympathetic inhibition thus to decreased blood pressure. Currently, centrally acting
antihypertensive drugs are not commonly used due to prominent side effects, including dry
mouth, sedation, dizziness and edema. However, other anti-hypertensives can also cause
xerostomia. For example, ganglion blockers and particularly b adrenergic receptor antagonists
(the so-called “b blockers”) such as timolol, atenolol and metoprolol may cause a dry mouth
Table 2. Medications causing xerostomia
Family Drug
Antidepressants MAOs, TCAs, SSRIs
Antihypertensives Clonidine, Guanfacine, Reserpine, Methyldopa, Timolol, Atenolol,
Metoprolol, Diltiazem, Verapamil, Nifedipine, Thiazides,
Furosemide
Antipsychotics Olanzapine, Clozapine, Haloperidol, Quetiapine, Risperidone,
Donepezil





Centrally acting skeletal muscle
relaxants
Tizanidine, Baclofen
Antihistamines Cetirizine, Acrivastine, Astemizole, Loratadine, Mizolastine
H2 receptor antagonists and
proton-pump inhibitors
Ranitidine, Omeprazole
Opioids and benzodiazepines Morphine, Dihydrocodeine, Tramadol, Diazepam
Cytotoxic drugs 5-flurourcail
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sensation. This effect is thought to result from the stimulation of a2 adrenergic receptors found
on the salivary glands and in the CNS [4]. A study comparing the effects of non-selective and
b1-selective adrenergic receptor antagonists with placebo, showed that it was largely the
composition of saliva that was affected by the b adrenergic receptor antagonists rather than
salivary flow rate. The most notable changes with b adrenergic receptor antagonists were drastic
decreases in total protein composition and amylase activity, while salivary flow rates remained
within normal values.
Another principal group of hypertensive drugs is the angiotensin-converting enzyme (ACE)
inhibitors. Drugs of this group have long been used as one of the most important pharmaco-
logical tools for the treatment of arterial hypertension, and are also used for other cardiovascular
indications. In addition to its ability to convert angiotensin I, ACE also has kinase activity, which
prevents the accumulation of tissue mediators such as bradykinin. When this enzyme is
inhibited, bradykinin molecules accumulate, leading to a number of adverse reactions.
According to the available data, approximately 8–13% of patients using ACE inhibitors report
xerostomia [13].
Diuretics are the most commonly prescribed drugs for cardiovascular disease and hyper-
tension in the USA, and act by affecting the reabsorption of sodium in the kidneys, thus
influencing the blood volume and pressure. The thiazide subgroup of diuretics act via the in-
hibition of the sodium-chloride cotransporter, found in the distal convoluted tubules of the
nephron. The loop diuretics also act on sodium regulation in the kidneys are the loop diuretics.
Furosemide, a loop diuretic agent, targets the sodium-potassium-chloride cotransporter found
on the thick ascending limb of the nephron [14]. In a study following the side effects of ther-
apeutic agents in elderly patients, diuretics and psychotropics were the most common medi-
cations inducing xerostomia and caused similar reduction of mean salivary flow rates [15].
Another study evaluating the side effects of furosemide also reported oral dryness as a side effect.
During the study, urine and salivary secretions were obtained from five normal males after the
oral intake of either 0.5 mg/kg body weight of furosemide or placebo. As expected, patients
administered the drug showed a dramatic increase in urinary output and increased reports of
xerostomia. However, there were no significant differences in salivary flow rate, total salivary
output, total protein amount in the saliva or ion concentrations in saliva in patients receiving the
drug. These findings have led to the conclusion that furosemide had a more notable effect on the
kidneys than on the salivary glands, and that the sensation of oral dryness in this case may not
be related to the quantity of salivary output [16].
Other antihypertensive drugs with salivary side effects include the widely used calcium
channel blockers such as diltiazem, verapamil and nifedipine. These agents can cause xerostomia
due to their effects on calcium regulation which has an essential role in saliva secretion [17].
Antipsychotics
Antipsychotic drugs are widely known to cause extrapyramidal symptoms, the most common
side effects for these drugs. These symptoms include continuous muscle contractions, motor
restlessness, muscle rigidity, slower movements, tremors, and the appearance of irregular
movements. The mechanism of action for these symptoms is the inhibition of dopamine D2
receptors, or the eradication of the neurotransmitter from the basal ganglia. The functional
absence of dopamine often leads to a pathological state of the extrapyramidal system [18]. In
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addition to these extrapyramidal symptoms, some antipsychotic medications also possess
anticholinergic properties. Although newer drugs have been developed, both old and new
antipsychotic medications can lead to a wide range of side effects. Despite the fact some of the
antipsychotic agents have a selective affinity for D2 receptors, they continue to exhibit anti-
cholinergic effects. These anticholinergic effects have particular importance, as one of the main
side effects reported by patients using these medications is xerostomia [19]. It has been
demonstrated that a long term and continuous treatment of schizophrenia with conventional
antipsychotics is highly linked to anticholinergic side effects including dry mouth. Olanzapine,
an atypical antipsychotic, was found to have a positive therapeutic effect on schizophrenia
patients, but adverse reactions such as dizziness and dry mouth were very prominent [4, 20].
Despite the associated effects, this drug is highly recommended in the treatment of patients with
schizophrenia and related psychoses. Another atypical antipsychotic agent, clozapine, shares
similar biochemical and pharmacological characteristics with those of olanzapine. A study
comparing the usage of clozapine and olanzapine, both atypical antipsychotic drugs, showed
that patients treated with olanzapine had significantly fewer instances of adverse effects (4%)
than those who were treated with clozapine (14%). Strikingly, one of the most reported side
effects was increased salivation, which was observed more frequently in patients treated with
clozapine [21]. A study comparing olanzapine with haloperidol, a typical antipsychotic drug, has
shown that olanzapine causes xerostomia more frequently [22]. Similarly, another study of
atypical antipsychotics such as quetiapine and risperidone reported dry mouth in 14.5% and
6.9% of cases, respectively, and dry mouth more prevalent in the quetiapine group than the
placebo group [23].
Donepezil is an acetylcholinesterase inhibitor that is marketed for the treatment of Alz-
heimer’s disease. This disease results in memory loss and behavioral deterioration and is
associated with by a deficit of acetylcholine. However, this drug is also used as an antipsychotic,
usually in combination with other antipsychotic agents. Donepezil can improve memory loss
and has the ability to counteract the xerostomia caused by other antipsychotics. Unfortunately,
donepezil can also trigger mania, a major risk that must be considered when weighing its
benefits [24].
Bronchodilators
Bronchodilators are the most prominent class of medications used to manage chronic
obstructive pulmonary disease (COPD), and are also critical for the management of asthma.
These drugs cause relaxation of airway smooth muscle cells of the airways, leading to bron-
chodilation. One main subgroup of bronchodilators is the b2 adrenergic receptor agonists,
which are further grouped based on their time of onset and duration of action. Example drugs in
in this class include the short acting albutamol and terbutaline, the longer acting salmeterol and
formoterol, and the ultra-long acting indacaterol. Even though xerostomia is not a commonly
reported side-effect, several agents in this group have a strong link to dental caries and peri-
odontal diseases [25]. Another subcategory of airway-dilating agents are the anticholinergics.
The two most well-known anticholinergics used as bronchodilators are tiotropium and ipra-
tropium. They show high receptor selectivity for the M1 and M3 receptors and, in common with
b-agonists, their main route of administration is inhalation [26]. According to a study exploring
the adverse effect of anti-asthma drugs, dry mouth is a common side effect, and the most
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commonly reported side-effect of tiotropium was xerostomia (9.3%). This is thought to be
related to inhibition of muscarinic receptors on the salivary glands [27]. The link between
anticholinergics and dry mouth were also confirmed in other studies assessing the side effects of
anti-asthma medications [28]. In addition to the studies demonstrating correlation between
bronchodilators and xerostomia, another study was conducted to examine the correlation be-
tween chronic medication use and 5‐year dental caries incidence among the elderly. The hy-
pothesis behind this study was that medications causing xerostomia could increase caries
incidence via two mechanisms. The first suggested mechanism is that medications associated
with xerostomia could increase dental caries by leading to a chronic decrease in salivary flow rate
and decreased capacity of saliva to buffer acids in the oral cavity. The second hypothesis is that
the occurrence of xerostomia would lead to consumption of sweet drinks and food in an effort to
relieve the dry mouth sensation, and thus increase caries incidence. The results indicated that
patients who were under anti-asthma drug treatment during the previous 5 years had presented
more cases of coronal caries than control patients, and it has been concluded that this group
of drugs is strongly associated with caries manifestation and with the appearance of
xerostomia [29].
Antimuscarinic agents for overactive bladder syndrome
The physiological function of the urinary system is largely under the control of M2 and M3
muscarinic receptors found on the smooth muscle of the urinary bladder, called the detrusor
muscle [4]. When stimulated, M2 receptors block adenyl cyclase, resulting in the inhibition of
the sympathetically-induced relaxation, leading to smooth muscle contraction, and in several
pathological conditions, M2 receptors can directly contribute to smooth muscle contraction.
From a therapeutic point of view, simultaneous inhibition of M2 and M3 receptors would be
optimal in ensuring the complete inhibition of smooth muscle contractions. Oxybutynin, a
widely used M3 receptor antagonist, and other similar drugs, are the most widely used therapy
for urinary system problems. Anticholinergic drugs used by people with overactive bladder
syndrome have proven to show large improvement in symptoms [30], with oxybutynin and
tolterodine the most widely used to treat this syndrome. However, the M3 receptors on the
urinary bladder are not the only target for this group of medications, and those therapeutic
agents can lead to many adverse effects including dry mouth due to inhibition of the M3 re-
ceptors located on the salivary glands [4]. A comparison of Tolterodine IR (immediate release)
and Oxybutynin IR showed that the two agents have similar efficacy, but that Tolterodine IR was
been better tolerated, in particular with regard to the incidence and severity of dry mouth [31].
Adverse reactions including dry mouth, constipation and even blurred vision, are closely related
to the anticholinergic activity of these drugs and occur frequently in up to 25% of patients,
depending on the dosage [32]. In recent years, research efforts have been focusing on the
development of drugs with selectivity to the muscarinic receptors found in the bladder, causing
fewer adverse effects such as dry mouth.
Centrally acting skeletal muscle relaxants
Tizanidine, a central a2 adrenergic receptor agonist, is widely used in the treatment of patients
suffering from spasticity associated with multiple sclerosis or any damage to the CNS. Tizani-
dine depresses muscle reflexes via both spinal and supra-spinal pathways, but the precise
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mechanism of action of this drug is not fully understood. In a study assessing the side effects
caused of tizanidine, the most common complaint was dry mouth [33]. In a study conducted
to compare the effects of baclofen, another widely used muscle relaxant, with those of tiza-
nidine, forty patients suffering from multiple sclerosis were randomized into baclofen or
tizanidine groups and treated for six weeks. Critically, dry mouth was frequently reported in
patients taking either medication [34]. In addition to its use in overactive bladder syndrome
discussed above, oxybutynin also has spasmolytic properties so may be present in this patient
population as well.
Antihistamines
Selective H1 antihistamines are the “gold standard” in treatment against symptoms arising
from allergic rhinitis [35]. These drugs function as inverse agonists, rather than antagonists of
histamine H1 receptors, members of the G-protein coupled receptor family. H1 antihistamines
were originally developed more than 70 years ago from other anticholinergic drugs, but the
older generation of H1 antihistamines penetrates the blood–brain-barrier and can cause a
sedating effect and tiredness, together with impaired memory and lower ability to concentrate
[36]. The drugs which belong to this group are small lipophilic molecules, and are associated
with several side effects largely due to their ability to cross the blood–brain barrier and alter
the physiologic cholinergic activity [35]. Medications belonging to the second generation of
selective H1 antihistamines are safer, reportedly causing fewer side effects [36]. This gener-
ation of antihistamines possesses more lipophobic properties, preventing the molecule from
penetrating the blood brain barrier and thereby blocking CNS and cholinergic effects. In
addition, this generation of medications has a longer duration of action allowing a more
patient-friendly dosing schedule, which may result in increased patient compliance with
therapy [35]. In a study investigating sedating vs. non-sedating antihistamines, the older
antihistamines caused pronounced CNS side effects as well as anticholinergic effects including
dry mouth. The newly developed medications are mostly H1 receptor antagonists, and
although they are not completely free from side effects, they did show a significantly lower
number of cases involving dry mouth. Second-generation antihistamines include cetirizine,
acrivastine, astemizole, loratadine and mizolastine [15].
H2 receptor antagonists and proton-pump inhibitors
The most common method for the eradication of Helicobacter pylori is treatment with three
main agents: amoxicillin or tetracycline, metronidazole, and a bismuth derivative. A controlled
trial has investigated whether the addition of H2 receptor antagonist such as ranitidine, can
accelerate the treatment process, and results demonstrated that this was indeed effective for the
eradication of the bacteria. Unfortunately, addition of ranitidine increased incidence of several
side effects including dry mouth, found in 41% of recipients [37]. Proton-pump inhibitors are
used to decrease the volume of gastric juice and acid secretion. Drugs in this group, such as
omeprazole, act by irreversibly inhibiting the hydrogen/potassium ATPase enzymes, found on
gastric parietal cells. A study evaluating the usage of omeprazole reported that several patients
administered omeprazole for more than six weeks complained of a dry mouth [38]. In addition,
four out of the six patients experiencing xerostomia had altered salivary flow rates while un-
dergoing treatment, and after cessation of the treatment, flow rates returned to normal. When
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saliva from the patients was cultured, significant amounts of Candida albicans were able to grow
in the cultured saliva. These three patients out of the six were the ones with the lowest flow rates.
Growth of Staphylococcus aureus was also recorded in one of the samples. The conclusion drawn
from this study was that despite the correction of salivary flow rates upon cessation of omep-
razole use, a dangerous window inviting opportunistic infections is open during the period of
usage, especially in edentulous patients [38].
Opioids and benzodiazepines
Opioids such as morphine and benzodiazepines are commonly used to facilitate patient comfort
and aid in mechanical ventilation. Unfortunately, none of these agents embody all the char-
acteristics of an ideal sedative or analgesic agent, so they are given in combination [39]. Opioids
are well-known to cause dry mouth. For example, a study investigating morphine responses in
human patients reported a high incidence of dry mouth [40]. Similarly, a study evaluating
controlled‐release morphine sulfate reported several side effects including dry mouth [41].
Another opioid, dihydrocodeine, has been reported to cause dry mouth in 80% of the patients
receiving it [42]. Tramadol, a synthetic, centrally acting analgesic agent, has also displayed dry
mouth as one of its most common adverse reactions, with an incidence of 1.6–6.1% [43].
Benzodiazepines are widely used as anxiolytics, hypnotics, anticonvulsants and muscle relaxants.
They act by enhancing GABA-A receptor function in the CNS [44]. Members of this group, such
as diazepam, may also cause a slight dry mouth sensation [45].
Cytotoxic agents
Administration of cytotoxic drugs may result in complicated oral manifestations. The major
effect of cytotoxic agents is suppression of the immune system, but they can also directly damage
the oral mucosa. For example, the common cytotoxic drugs 5-flurourcail, is frequently associ-
ated with xerostomia [4]. Xerostomia during chemotherapy is also a major reason for the
development of mucositis likely due to the low level of neutrophils caused by immunosup-
pressing medications [46]. This damage caused by cytotoxic drugs can be intensified when
considering xerostomia and secondary infections [47]. A study comparing healthy patients with
patients undergoing chemotherapy found differences in the characteristics of saliva between the
two groups [47]. Based on these findings, a more elaborate study was initiated in patients taking
cytotoxic medications to evaluate the volume and composition of saliva as well as potential
pathogens in the oral cavity. Twelve patients were evaluated before and after the beginning of
cytotoxic therapy. They were also evaluated four weeks and twelve weeks after the cessation of
treatment. In samples collected twelve weeks after treatment was completed, the amounts of
saliva was significantly reduced. The composition of the saliva was also altered, and important
components such as Immunoglobulin A and amylase were decreased. The only component of
saliva that remained within normal value was lysozyme. The study also reported large growth of
Candida species in the saliva as well as S. aureus in some samples. This study concluded that
cytotoxic chemotherapy is a leading cause for reduced salivary flow, altered saliva composition,
and an oral environment that allowed for increased growth of opportunistic pathogens [47].
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DISCUSSION AND CONCLUSIONS
Although an immense number of therapeutic agents can cause undesirable oral side effects and
many of these agents are used to treat very common conditions, the importance of oral side
effects of medications is underestimated by dentists. In addition, drug-induced oral adverse
reactions are a common issue raised by dental patients. In most cases, resolution of these side
effects can be achieved by withdrawal and replacement of the agent in question, coupled with a
symptomatic therapy. Unfortunately cessation or replacement of the medication is not always an
option. As such, best dental practice should include an extensive knowledge of possible com-
plications, careful patient monitoring, and proper case management. Treatment of symptoms
substitution or withdrawal of responsible medications are important, but they are not the only
steps in a treatment plan. Maintenance of good oral hygiene, cessation of bad habits such as
alcohol consumption and smoking, adequate nutrition and vitamin intake, and proper hydra-
tion can all influence the extent of the undesirable effects of medication usage [48]. As one of the
most common oral reactions related to medication usage, xerostomia also has several phar-
maceutical treatments such as saliva stimulants. After carefully considering the mechanisms and
likely causes of xerostomia, the dentist should develop an individual and appropriate treatment
plan for each affected patient. Some saliva stimulants require a prescription, while some do not.
These agents come in the form of mouthwash, saliva substitute gels, toothpastes, patches and
even sugar-free chewing gums, and can assist in the relief of dry mouth sensation. However, the
use of such therapeutic agents does not always result in relief of symptoms, and it does not
enable a higher-dose of the reaction-inducing medication [49]. Lastly, it is important to high-
light that the field of pharmacology progresses rapidly as new therapies are developed and
clinicians should pay special attention to the therapeutic agents used by their patients. It is
necessary to understand both the mechanisms by which the drugs act, as well as their potential
adverse effects [50].
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